Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

REGENERA MS

Financiado

Neuroregenerative peptide treatment for multiple sclerosis

REGENERA MS will assess the technical and commercial feasibility of a novel peptide as a superior treatment for multiple sclerosis (MS). Successful commercialization of our peptide could reduce the socioeconomic burden of MS, prov... ver más

31/12/2025

HELSINGIN YLIOPIST...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

HELSINGIN YLIOPISTO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-12

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS Objective:Objectives:The ERC Proof of Concept Grants aim at facilitating exploration of the commerci...

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

HELSINGIN YLIOPISTO

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

IPT-2011-1312-900000 Desarrollo de terapias neuroprotectoras para Esclerosis Múlt... 715K€ Cerrado

PTQ-10-03816 Investigación y desarrollo de nuevos fármacos neuroprotector... 114K€ Cerrado

SAF2009-13015-C02-01 DISEÑO, SINTESIS Y EVALUACION DE FARMACOS NEUROGENICOS COMO... 242K€ Cerrado

BFU2014-59009-P EFECTO DE DENDRIMEROS ANTIINFLAMATORIOS SOBRE LA PATOGENESIS... 182K€ Cerrado

PTQ-11-04550 Nuevas terapias farmacológicas para el tratamiento de enferm... 36K€ Cerrado

IPT-010000-2010-035 Nuevas aproximaciones terapéuticas para la Esclerosis Múltip... 487K€ Cerrado

Duración del proyecto: 22 meses Fecha Inicio: 2024-02-12
Fecha Fin: 2025-12-31

Líder del proyecto

HELSINGIN YLIOPISTO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto REGENERA MS will assess the technical and commercial feasibility of a novel peptide as a superior treatment for multiple sclerosis (MS). Successful commercialization of our peptide could reduce the socioeconomic burden of MS, provide an early-therapy option to delay disease progression and thus extend and improve patients’ lives, with potential effectiveness in related neurodegenerative diseases. MS is a chronic inflammatory, autoimmune, and neurological disease without a cure, affecting the lives of 1.2M Europeans and causing significant economic costs to patients and society. Currently, there is no cure for MS. Approved disease-modifying treatments such as IFN-β1, glatiramer acetate and alemtuzumab are clinically effective but come with high costs, significant side-effects, and intrusive administration. Thus, a medical unmet need remains for novel MS therapies that can halt progression, promote myelin repair and limit complications. To improve on the current therapeutic regimen, we propose a next-generation neurotrophic factor (NTF) therapy that has curative potential by halting MS progression and regenerating demyelinated tissue. My group has discovered a novel peptide with neurotrophic properties and which, in contrast to classical NTFs, (i) has neurorestorative effects and can enhance remyelination (ii) penetrates the blood-brain barrier (BBB), (iii) can be subcutaneously administered, and (iv) can be inexpensively produced. In REGENERA MS, we will evaluate the pharmacokinetic properties and efficacy of a novel therapeutic peptide in organotypic brain cultures, human induced oligodendrocyte-like pluripotent stem cell-derived cells and in MS animal models. Subsequently, we will verify the IP position and strategy, perform an in-depth market and competitor analysis, and finally consolidate these findings into a business case to establish the best path to commercialization.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores